NBC Securities Inc. Increases Stock Holdings in Cencora, Inc. (NYSE:COR)

NBC Securities Inc. increased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 125,080.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,259 shares of the company's stock after purchasing an additional 6,254 shares during the quarter. NBC Securities Inc.'s holdings in Cencora were worth $1,740,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. JFS Wealth Advisors LLC grew its position in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new position in Cencora during the fourth quarter valued at approximately $29,000. SBI Securities Co. Ltd. bought a new position in Cencora during the fourth quarter valued at approximately $30,000. Kentucky Trust Co bought a new position in Cencora during the fourth quarter valued at approximately $33,000. Finally, WASHINGTON TRUST Co boosted its stake in Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now directly owns 315,913 shares in the company, valued at approximately $89,027,442.53. This trade represents a 4.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,253 shares of company stock worth $11,102,417 over the last three months. 10.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Bank of America raised their price objective on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $274.00 to $337.00 in a research note on Tuesday. Robert W. Baird raised their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, UBS Group raised their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $306.91.

Cencora Trading Down 0.9%

COR stock traded down $2.53 during mid-day trading on Wednesday, reaching $289.02. The company had a trading volume of 811,433 shares, compared to its average volume of 1,530,768. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a market capitalization of $56.02 billion, a PE ratio of 41.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The firm has a 50 day moving average of $285.59 and a 200 day moving average of $259.30. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.80 earnings per share. On average, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. Cencora's payout ratio is currently 25.52%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.